Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report issued on Saturday. The firm set a “hold” rating on the stock.

Several other brokerages have also issued reports on CTLT. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Shares of Catalent stock opened at $63.48 on Friday. The stock’s 50-day moving average is $61.27 and its 200 day moving average is $59.87. Catalent has a one year low of $41.15 and a one year high of $63.50. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) earnings per share. Equities research analysts anticipate that Catalent will post 0.78 EPS for the current year.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

Hedge funds and other institutional investors have recently bought and sold shares of the company. Athos Capital Ltd bought a new position in shares of Catalent in the third quarter worth $6,009,000. Oddo BHF Asset Management Sas purchased a new position in Catalent during the third quarter worth about $8,480,000. State Street Corp increased its stake in Catalent by 1.5% in the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after acquiring an additional 113,095 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Catalent in the 3rd quarter valued at about $1,131,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after acquiring an additional 14,373 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.